key: cord-1031467-fcllxr41
authors: Morais‐Almeida, Mário; Barbosa, Miguel T.; Sousa, Cláudia S.; Aguiar, Rita; Bousquet, Jean
title: Update on asthma prevalence in severe COVID‐19 patients
date: 2020-07-08
journal: Allergy
DOI: 10.1111/all.14482
sha: 7abc008948e36df6f7f8e8c0747ab069f29429b2
doc_id: 1031467
cord_uid: fcllxr41

We carefully read the recently published research letter “Is asthma protective of COVID‐19?” by Carli et al.(1) with great interest. Important topics for asthma patients during the coronavirus disease 2019 (COVID‐19) pandemic were discussed, including that until recently there was limited evidence that patients with chronic respiratory disorders are at lower risk of being infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) or becoming severely ill.

*Both authors contributed equally to this paper

We carefully read the recently published research letter "Is asthma protective of COVID-19?" by Carli et al. 1 with great interest. Important topics for asthma patients during the coronavirus disease 2019 (COVID-19) pandemic were discussed, including that until recently there was limited evidence that patients with chronic respiratory disorders are at lower risk of being infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or becoming severely ill.

This article is protected by copyright. All rights reserved Only taking into account previous reports from China and Italy, where asthma was underrepresented in COVID-19 patients, the authors acknowledge the heterogeneous condition that is asthma, suggesting that T2-immunity, interferon-mediated immune responses and increased number of eosinophils in the airways could have a protective effect against COVID-19 severity. 1 The epidemiology of COVID-19 is changing rapidly with new data. More recent reports from the United States of America and from several European countries, in particular the United Kingdom (UK), states a higher asthma prevalence in patients with COVID-19, suggesting that asthma is more common in COVID-19 patients than it was previously reported in Asia and in the first European surveys. 2 Data from the UK Biobank, a large prospective case-control study, found an asthma prevalence of 17,9% in 605 COVID-19 hospitalized patients, mostly of them adults, surpassing the prevalence of asthma in the general population. 3 In the OpenSAFELY Collaborative Study (UK), a significant increased risk of severe COVID-19 disease and mortality rate was found in patients with asthma, particularly in patients with recent oral corticosteroids (OCS) use. 4 These findings indicate an increased asthma severity and/or poor control, and in accordance with data from previous coronavirus outbreaks, that the use of systemic corticosteroids can be associated with a higher viral load. 5 We agree with Carli et al 1 that further studies focused on asthma and its different phenotypes are needed to improve our understanding of the association between asthma and COVID-19 severity. 6 Factors as coviral infections, that were quite low in the first Chinese and Italian reports, or different exposures to allergens or irritants, as tobacco smoke, can justify some of the differences found in asthma prevalence between the available case-series.

Based on current recommendations, it is crucial that patients with asthma do not stop their controller medication, which may lead to a higher risk of asthma exacerbations, emergency room visits, hospitalization, and increased use of OCS.

In conclusion, according to the available data, patients with asthma must still be included in the high-risk COVID-19 groups and further research is warranted to improve our understanding of the relationship between asthma and COVID-19.

Is asthma protective of COVID-19? Allergy

Asthma and the COVID-19 pandemic: literature review. Int Arch Allergy Immunol

Associations with COVID-19 hospitalisation amongst 406,793 adults: the UK Biobank prospective cohort study

The OpenSAFELY Collaborative. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients

Coronavirus RNA concentrations in adult patients

COVID-19 and asthma: To have or not to have T2 inflammation makes a difference? Pulmonology

This article is protected by copyright. All rights reserved Dr. Morais-Almeida has nothing to disclose.Dr. Barbosa has nothing to disclose.Dr. Sousa has nothing to disclose.Dr. Aguiar has nothing to disclose.Dr. Bousquet has nothing to disclose.